Form 4: Swartz Robin reports sale transactions in VYGR

Rhea-AI Filing Summary

Swartz Robin reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 4,569 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 210,078 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swartz Robin

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & CBO

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S(1)		4,569(1)	D	$3.85(2)	210,078	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.72 to $3.90, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Robin Swartz	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Voyager Therapeutics (VYGR) report for Robin Swartz?

Voyager Therapeutics reported that COO & CBO Robin Swartz sold 4,569 shares of common stock on February 10, 2026 at a weighted average price of $3.85 per share, in an automatic tax-related transaction.

Why did Robin Swartz sell Voyager Therapeutics (VYGR) shares in February 2026?

The sale was made under a durable automatic sales instruction letter to sell shares to cover tax withholding obligations tied to restricted stock units vesting on February 9, 2026, and is described as non-discretionary by the officer.

How many Voyager Therapeutics (VYGR) shares does Robin Swartz own after the reported sale?

After selling 4,569 shares, Robin Swartz directly owns 210,078 shares of Voyager Therapeutics common stock. This figure reflects her beneficial ownership immediately following the February 10, 2026 tax-related transaction disclosed in the Form 4 filing.

What was the price range for Robin Swartz’s Voyager Therapeutics (VYGR) share sale?

The weighted average sale price reported is $3.85 per share. Footnotes explain the shares were sold in multiple transactions at prices ranging from $3.72 to $3.90 per share, with detailed breakdowns available upon regulatory request.

Was Robin Swartz’s Voyager Therapeutics (VYGR) share sale considered an open-market trade?

The transaction is coded as an open-market sale, but the filing clarifies it was executed under a durable automatic sales instruction solely to cover tax withholding obligations, and does not represent a discretionary trade by Swartz.

What role does Robin Swartz hold at Voyager Therapeutics (VYGR)?

Robin Swartz is identified as an officer of Voyager Therapeutics, serving as COO & CBO. Her position and insider status require reporting transactions like the February 10, 2026 tax-related sale of common stock on a Form 4.